Atomwise pursues 15 collaborations for COVID-19 treatments

By The Science Advisory Board staff writers

May 22, 2020 -- Small molecule drug discovery company Atomwise has announced it is collaborating with 15 institutions to develop broad-spectrum therapies for coronaviruses, including the novel coronavirus responsible for COVID-19.

Participating institutions include the following:

  • University of Mannitoba
  • Columbia University
  • University of Connecticut
  • University of Kentucky
  • University of South Australia
  • University of Texas Medical Branch Health
  • Jazan University
  • Dana-Farber Cancer Institute
  • University of Texas Health Science Center at San Antonio
  • University of Toledo
AGC to manufacture Takara Bio's COVID-19 vaccine
In the fight against COVID-19, AGC Biologics, a contract development and manufacturing organization, is partnering with Takara Bio to manufacture plasmid...
New platform includes biological similarities to accelerate drug discovery
A new open-access tool provides information on the effects of nearly 1 million compounds in a wide range of biological settings. The new tool, published...
Bharat, TJU partnering on COVID-19 vaccine
Bharat Biotech and Thomas Jefferson University (TJU) of Philadelphia have signed a deal to develop a new vaccine for COVID-19.
Human enzymes are implicated in SARS-CoV-2 evolution and spread
Two human deaminase enzymes that edit viral RNA inside cells could have implications for the evolution of SARS-CoV-2 and the spread of the infection,...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
2020 ACCP Annual Meeting
September 20-22
Bethesda, Maryland United States
Bioprocess International West
September 21-24
Eastern Standard Time Zone (EST) United States
BioProcess International
September 21-24
Eastern Standard Time Zone (EST), Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter